Recent Updates
Recently added Catalysts
EOLS Neutral Sentiment

Evolus to Participate in The Jefferies Global Healthcare Conference

Key Takeaway: Evolus is set to participate in the Jefferies Global Healthcare Conference. The event will provide a platform for the company to discuss its strategies and developments in the healthcare sector. Further details about the conference and Evolus's specific agenda have not been disclosed.
Price reaction · baseline $6.57 (2026-05-18 close) · hit after-hours · clean, no other EOLS news in the window
day 0 close · peak
-2.1%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~37 mo
Minimal dilution risk
Lead asset
PrabotulinumtoxinA-Xvfs
Phase 2 · Glabellar Frown Lines

Full Press Release Details

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc.(NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Jefferies Global Healthcare Conference in New York City.
The fireside chat will take place on Thursday, June 4th, 2026, at 12:50 PM ET.
The fireside chat can be accessed on the Investor Relations page of the Evolus websitehere. A replay of the webcast will be available 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau®(prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us atwww.evolus.com, and follow us onLinkedIn,X,InstagramorFacebook.
Jeuveau®, Nuceiva®, and Evolysse®are registered trademarks of Evolus, Inc.
Last updated: May 19, 2026